GLP-1 receptor agonists in dermatology

The rapid expansion of glucagon-like peptide-1 receptor agonist (GLP-1 RA) approvals has created a complex regulatory and practice environment for dermatologists. No GLP-1 RA currently holds a United States Food and Drug Administration (FDA)-approved dermatologic indication; all prescribing for cutaneous conditions-including psoriasis, hidradenitis suppurativa, and wound healing-remains off-label. This chapter examines the regulatory frameworks governing GLP-1 RA use in dermatology, encompassing the current FDA-approved landscape, legal and professional standards for off-label prescribing, obesity medicine certification as a competency pathway, the compounding controversy, and access, cost, and reimbursement barriers. Particular attention is given to the Anti-Kickback Statute implications of manufacturer copay cards for Medicare beneficiaries, the Treat and Reduce Obesity Act, and evolving patient assistance strategies. Multidisciplinary collaboration, adverse event surveillance, the next-generation incretin pipeline, and ethical and equity considerations are also addressed. Practical recommendations are provided to guide dermatologists in navigating prescribing authority, reimbursement, pharmacovigilance, and the evolving evidence base.

Abstract from PubMed